With CGM now part of the Diabetes Canada Clinical Practice Guidelines, Dexcom CGM use is proven to improve glycemic control 1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring. 3 BURNABY, British Columbia --(BUSINESS WIRE)--Jun.

SAN DIEGO --(BUSINESS WIRE)--May 31, 2022-- DexCom, Inc. (NASDAQ:DXCM) today issued the following statement in response to recent media and market speculation: “Like many companies, Dexcom’s Board and management team regularly review opportunities to enhance stockholder value and create benefits

SAN DIEGO --(BUSINESS WIRE)--May 23, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that Brice Bobzien , Senior Vice President, Finance, will present an update on the company at the Piper Sandler Ophthalmology and Diabetes Symposium on Wednesday, May 25, 2022 at 1:00 p.m. (EDT) .

SAN DIEGO --(BUSINESS WIRE)--May 10, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain , Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor conferences: BofA Securities 2022 Healthcare Conference on

SAN DIEGO --(BUSINESS WIRE)--Apr. 28, 2022-- DexCom, Inc. has updated its first quarter 2022 earnings call due to technical difficulties with the conference call provider. The conference call will now start at 5:30 p.m. (Eastern Time) . The link to the webcast will be available on the DexCom, Inc.

SAN DIEGO --(BUSINESS WIRE)--Apr. 28, 2022-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2022 . First Quarter 2022 Financial Highlights: Revenue grew 25% versus the same quarter of the prior year to $628.8 million on a reported basis

New portfolio of continuous glucose monitoring systems includes Dexcom ONE, Dexcom G6 and the upcoming Dexcom G7, which recently received CE Mark and is currently under FDA review 1 The expanded range of products offers the most innovative, connected and accessible CGM options available for people

Beginning mid-April, TRICARE® members will have faster and more convenient access to the Dexcom G6 Continuous Glucose Monitoring (CGM) System Dexcom G6 will be available as a brand-name formulary pharmacy benefit to military members, retirees and their families SAN DIEGO – April XX, 2022 – DexCom,

Report advances Dexcom’s environmental, social, and governance (ESG) transparency by providing new disclosures including company’s first Sustainability Accounting Standards Board (SASB) index SAN DIEGO --(BUSINESS WIRE)--Apr. 7, 2022-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time

On the heels of the latest NICE guidelines, Dexcom ONE is in review by NHS England for addition to the Drug Tariff LONDON --(BUSINESS WIRE)--Apr. 1, 2022-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the new